M&A / Acquisition · MENA · Announced 26 Oct 2026
Rameda → Art Pharma
M&A / Acquisition deal between Rameda (Egypt) and Art Pharma (Egypt), announced 26 Oct 2026. Value: $20m.
Parties: Rameda (Egypt) → Art Pharma for Pharmaceutical Industries (Egypt)
- Deal type
- M&A / Acquisition
- Value
- $20m
- Territory
- Egypt
- Therapeutic area
- Other
- Asset
- 100% of Art Pharma via all-share swap — sterile ampoule GMP site (6th October City); 90% minimum acceptance; est. 6–13% dilution
- Announced
- 26 Oct 2026
Our analysis
On 26 October 2026, Rameda's board approved a proposal to acquire 100% of Art Pharma for Pharmaceutical Industries via an all-share swap. No value was disclosed — but the public numbers around both companies allow a full valuation, synergy and dilution analysis of what is effectively Egypt's first listed-equity pharma roll-up.
The full analysis is free to read with a work email on this page.
Source: Al Borsa News (البورصة)